 |
|
|
| |
STANDARD VERSUS DOUBLE DOSE DOLUTEGRAVIR WITH
HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS
|
| |
| |
CROI 2023 Feb 20-23
Rulan Griesel1,2, Ying Zhao2,3, Bryony Simmons4, Zaayid Omar2, Andrew Hill4, Graeme Meintjes2,3, Gary Maartens1,2
1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
2Wellcome Centre for Infectious Disease Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
3Department of Medicine, University of Cape Town, Cape Town, South Africa
4Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom
|
| |
|
|
|
|
|
